PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Alpine Immune Sciences, Inc. (ALPN)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS02083G1004
CUSIP02083G100
SectorHealthcare
IndustryBiotechnology

Highlights

Market Cap$4.23B
EPS-$0.64
Revenue (TTM)$58.88M
Gross Profit (TTM)-$40.18M
EBITDA (TTM)-$43.67M
Year Range$6.71 - $64.57
Target Price$62.00
Short %13.14%
Short Ratio4.15

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Alpine Immune Sciences, Inc.

Popular comparisons: ALPN vs. RXST, ALPN vs. AAOI

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Alpine Immune Sciences, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-100.00%-50.00%0.00%50.00%100.00%150.00%NovemberDecember2024FebruaryMarchApril
8.21%
138.55%
ALPN (Alpine Immune Sciences, Inc.)
Benchmark (^GSPC)

S&P 500

Returns By Period

Alpine Immune Sciences, Inc. had a return of 238.82% year-to-date (YTD) and 801.96% in the last 12 months.


PeriodReturnBenchmark
Year-To-Date238.82%5.05%
1 month64.16%-4.27%
6 months614.38%18.82%
1 year801.96%21.22%
5 years (annualized)58.46%11.38%
10 years (annualized)N/A10.42%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
202439.61%32.36%12.55%
2023-7.29%-10.57%51.37%22.97%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current risk-adjusted rank of ALPN is 100, placing it in the top 0% of the market in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.

The Risk-Adjusted Performance Rank of ALPN is 100100
Alpine Immune Sciences, Inc.(ALPN)
The Sharpe Ratio Rank of ALPN is 100100Sharpe Ratio Rank
The Sortino Ratio Rank of ALPN is 9999Sortino Ratio Rank
The Omega Ratio Rank of ALPN is 9999Omega Ratio Rank
The Calmar Ratio Rank of ALPN is 100100Calmar Ratio Rank
The Martin Ratio Rank of ALPN is 100100Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Alpine Immune Sciences, Inc. (ALPN) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


ALPN
Sharpe ratio
The chart of Sharpe ratio for ALPN, currently valued at 9.45, compared to the broader market-2.00-1.000.001.002.003.009.45
Sortino ratio
The chart of Sortino ratio for ALPN, currently valued at 7.24, compared to the broader market-4.00-2.000.002.004.007.24
Omega ratio
The chart of Omega ratio for ALPN, currently valued at 1.89, compared to the broader market0.501.001.501.89
Calmar ratio
The chart of Calmar ratio for ALPN, currently valued at 8.68, compared to the broader market0.001.002.003.004.005.008.68
Martin ratio
The chart of Martin ratio for ALPN, currently valued at 71.01, compared to the broader market0.0010.0020.0030.0071.01
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 1.81, compared to the broader market-2.00-1.000.001.002.003.001.81
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 2.64, compared to the broader market-4.00-2.000.002.004.002.64
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.31, compared to the broader market0.501.001.501.32
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 1.38, compared to the broader market0.001.002.003.004.005.001.38
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 7.21, compared to the broader market0.0010.0020.0030.007.21

Sharpe Ratio

The current Alpine Immune Sciences, Inc. Sharpe ratio is 9.45. A Sharpe ratio of 3.0 or higher is considered excellent.


Rolling 12-month Sharpe Ratio0.002.004.006.008.0010.00NovemberDecember2024FebruaryMarchApril
9.45
1.81
ALPN (Alpine Immune Sciences, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Alpine Immune Sciences, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-80.00%-60.00%-40.00%-20.00%0.00%NovemberDecember2024FebruaryMarchApril
-19.92%
-4.64%
ALPN (Alpine Immune Sciences, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Alpine Immune Sciences, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Alpine Immune Sciences, Inc. was 97.33%, occurring on Mar 17, 2020. The portfolio has not yet recovered.

The current Alpine Immune Sciences, Inc. drawdown is 19.92%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-97.33%Aug 24, 20151149Mar 17, 2020
-12.05%Jul 20, 201511Aug 3, 201514Aug 21, 201525
-1.43%Jul 6, 20153Jul 8, 20152Jul 10, 20155
-1.14%Jul 13, 20151Jul 13, 20151Jul 14, 20152
-1.14%Jun 18, 20151Jun 18, 20156Jun 26, 20157

Volatility

Volatility Chart

The current Alpine Immune Sciences, Inc. volatility is 39.62%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%NovemberDecember2024FebruaryMarchApril
39.62%
3.30%
ALPN (Alpine Immune Sciences, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Alpine Immune Sciences, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items